Uso de probióticos no tratamento de pacientes com síndrome do intestino irritável / Use of probiotics in the treatment of patients with irritable bowel syndrome

Sophia de Araújo Libânio Costa, Sersie Lessa Antunes Costa Almeida, André Augusto Dias Silveira, Felipe Souza Guimarães, Gabriela Drummond Magalhães, Gabriela Mendes Nether, Isabela Angelles Floro Alonso, Juliana Alvarenga Jordão, Luiza Toscan, Mariza Corrêa Petrini, Yara Assumpção Machado de Almeida

Abstract


INTRODUÇÃO: A Síndrome do Intestino Irritável (SII) é um dos distúrbios funcionais mais comuns do sistema gastrointestinal e diferenças na composição da microbiota luminal de pacientes com SII foram observadas em grande parte dos níveis taxonômicos bacterianos. Portanto, a utilização de probióticos é considerada uma terapia alternativa e coadjuvante no tratamento. METODOLOGIA: Trata-se de um estudo qualitativo de revisão narrativa, no qual foram utilizadas as bases de dados PubMed, Google Scholar, Cochrane Library, EMBASE, MedLine, Scopus e Clinicaltrial.gov. Os descritores encontrados no DeCS e Emtree foram os seguintes: “terapia”, “síndrome do intestino irritável” e “probióticos”, tendo sido selecionados 24 artigos. RESULTADOS: A maioria dos resultados são promissores, porém não é possível definir com precisão qual probiótico ou qual associação de probióticos é eficaz, bem como qual é a dose e a duração do tratamento. DISCUSSÃO: Diversos estudos apontam os efeitos benéficos do uso da combinação de probióticos em pacientes com SII, mesmo que o mecanismo de ação desses microrganismos no alívio dos sintomas continue incerto. CONCLUSÃO: É necessária a realização de maior número de ensaios clínicos randomizados, a fim de determinar quais linhagens bacterianas, concentrações e duração do tratamento são mais efetivas na abordagem dos pacientes.


Keywords


Síndrome do intestino irritável, microbiota intestinal, probióticos.

References


CATINEAN, A. et al. Bacillus spp. Spores—A Promising Treatment Option for Patients with Irritable Bowel Syndrome. Nutrients, [S.L.], v. 11, n. 9, p. 1968, 21 ago. 2019. MDPI AG. http://dx.doi.org/10.3390/nu11091968.

CHONG. P. P.; CHIN, V. K.; LOOI, C.Y.; WONG, W. F.; MADHAVAN, P.; YONG, V. C. The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol. 2019; 10:1136. https://pubmed.ncbi.nlm.nih.gov/31244784/

DALE, H. F. et al. Probiotics in Irritable Bowel Syndrome: an up-to-date systematic review. Nutrients, [S.L.], v. 11, n. 9, p. 2048, 2 set. 2019. MDPI AG. http://dx.doi.org/10.3390/nu11092048.

DIDARI, T. et al. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World Journal Of Gastroenterology, [S.L.], v. 21, n. 10, p. 3072-3084, 14 mar. 2015. Baishideng Publishing Group Inc. http://dx.doi.org/10.3748/wjg.v21.i10.3072.

FORD, A. C. et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, [S.L.], v. 48, n. 10, p. 1044-1060, 8 out. 2018. Wiley. http://dx.doi.org/10.1111/apt.15001.

HAN, K. et al. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. Journal Of Gastroenterology, [S.L.], v. 52, n. 4, p. 432-443, 13 maio 2016. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s00535-016-1224-y.

HARPER, A. et al. The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome. Foods, [S.L.], v. 7, n. 2, p. 13, 26 jan. 2018. MDPI AG. http://dx.doi.org/10.3390/foods7020013.

KAJANDER, K. et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology & Therapeutics, [S.L.], v. 27, n. 1, p. 48-57, 5 out. 2007. Wiley. http://dx.doi.org/10.1111/j.1365-2036.2007.03542.x.

KONTUREK, P. C. et al. Therapeutische Modulation der Darmmikrobiota beim Reizdarmsyndrom. Mmw - Fortschritte Der Medizin, [S.L.], v. 159, n. 7, p. 1-5, 4 dez. 2017. Springer Science and Business Media LLC. https://doi.org/10.1007/s15006-017-0338-3.

LIANG, D. et al. Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. Medicine, [S.L.], v. 98, n. 27, p. 16068, jul. 2019. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/md.0000000000016068.

LYRA, A. et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo. World Journal Of Gastroenterology, [S.L.], v. 22, n. 48, p. 10631, 28 dez. 2016. Baishideng Publishing Group Inc. http://dx.doi.org/10.3748/wjg.v22.i48.10631.

MEZZASALMA, V. et al. A Randomized, Double-Blind, Placebo-Controlled Trial: the efficacy of multispecies probiotic supplementation in alleviating symptoms of irritable bowel syndrome associated with constipation. Biomed Research International, [S.L.], v. 2016, p. 1-10, 9 ago. 2016. Hindawi Limited. http://dx.doi.org/10.1155/2016/4740907.

OH, J. H. et al. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, [S.L.], v. 11, n. 12, p. 2887, 27 nov. 2019. MDPI AG. http://dx.doi.org/10.3390/nu11122887.

OOI, S. L. et al. Probiotics, prebiotics, and low FODMAP diet for irritable bowel syndrome – What is the current evidence? Complementary Therapies In Medicine, [S.L.], v. 43, p. 73-80, abr. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.ctim.2019.01.010.

PRESTON, K. et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Beneficial Microbes, [S.L.], v. 9, n. 5, p. 697-706, 11 jun. 2018. Wageningen Academic Publishers. http://dx.doi.org/10.3920/bm2017.0105.

PRINCIPI, N. et al. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. Journal Of Infection, [S.L.], v. 76, n. 2, p. 111-120, 29 dez. 2017. Elsevier BV. http://dx.doi.org/10.1016/j.jinf.2017.12.013.

PUSCEDDU, M. M. et al. Targeting the Microbiota, from Irritable Bowel Syndrome to Mood Disorders: Focus on Probiotics and Prebiotics. Current Pathobiology Reports, [S.L.], v. 6, n. 1, p. 1-13, 12 fev. 2018. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s40139-018-0160-3.

SISSON, G. et al. Randomised clinical trial: a liquid multi‐strain probiotic vs. placebo in the irritable bowel syndrome – a 12 week double‐blind study. Alimentary Pharmacology & Therapeutics, [S.L.], v. 40, n. 1, p. 51-62, 11 maio 2014. Wiley. http://dx.doi.org/10.1111/apt.12787.

SPILLER, R. et al. Review article: probiotics and prebiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, [S.L.], v. 28, n. 4, p. 385-396, 4 jun. 2008. Wiley. http://dx.doi.org/10.1111/j.1365-2036.2008.03750.x.

STAUDACHER, H. M. et al. Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low fodmap diet. Proceedings Of The Nutrition Society, [S.L.], v. 75, n. 3, p. 306-318, 24 fev. 2016. Cambridge University Press (CUP). http://dx.doi.org/10.1017/s0029665116000021.

SUN, J. R. et al. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. The Saudi Journal Of Gastroenterology, [S.L.], p. 66-77, 2019. Medknow. http://dx.doi.org/10.4103/sjg.sjg_384_19.

WEN, Y. et al. The efficacy and safety of probiotics for patients with constipationpredominant irritable bowel syndrome: A systematic review and metaanalysis based on seventeen randomized controlled trials. International Journal Of Surgery, [S.L.], v. 79, p. 111-119, jul. 2020. Elsevier BV. http://dx.doi.org/10.1016/j.ijsu.2020.04.063.

YUAN, F. et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Current Medical Research And Opinion, [S.L.], v. 33, n. 7, p. 1191-1197, 7 mar. 2017. Informa UK Limited. http://dx.doi.org/10.1080/03007995.2017.1292230.

ZHANG, Y. et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. Bmc Gastroenterology, [S.L.], v. 16, n. 1, p. 1-11, 13 jun. 2016. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12876-016-0470-z.




DOI: https://doi.org/10.34119/bjhrv3n4-358

Refbacks

  • There are currently no refbacks.